Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
评估福泰制药：来自11位财务分析师的见解
Exploring Analyst Ratings: An In-Depth Overview...Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX) in the last three months.
在过去三个月中，有11位分析师就福泰制药（纳斯达克：VRTX）发布了从看好到看淡的多元化观点。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您将找到他们最近的评级摘要，揭示了过去30天内情绪的变化，并将它们与前几个月进行比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $495.09, a high estimate of $600.00, and a low estimate of $425.00. Witnessing a positive shift, the current average has risen by 1.47% from the previous average price target of $487.90.
分析师评估的12个月价格目标揭示了更多见解，平均目标为495.09美元，最高估价为600.00美元，最低估价为425.00美元。目前平均价已经上升了1.47%，达到487.90美元之前的平均价格目标。
Exploring Analyst Ratings: An In-Depth Overview...
分析师评级:深...
登录免费看全文
登录/注册
资讯热榜
更新时间